Bank of New York Mellon
CTXR icon

Bank of New York Mellon’s Citius Pharmaceuticals CTXR Stock Holding History

Bank of New York Mellon’s Portfolio CTXR Stock Details CTXR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-585
Closed -$7.33K – 4129
2024
Q3 		$7.33K Hold
585
– – ﹤0.01% 4084
2024
Q2 		$8.54K Sell
585
-12,229
-95% -$219K ﹤0.01% 4104
2024
Q1 		$287K Sell
12,814
-879
-6% -$16.1K ﹤0.01% 3792
2023
Q4 		$259K Hold
13,693
– – ﹤0.01% 3859
2023
Q3 		$234K Hold
13,693
– – ﹤0.01% 3906
2023
Q2 		$411K Buy
13,693
+11,592
+552% +$382K ﹤0.01% 3699
2023
Q1 		$61.5K Hold
2,101
– – ﹤0.01% 4162
2022
Q4 		$41.5K Hold
2,101
– – ﹤0.01% 4265
2022
Q3 		$64K Hold
2,101
– – ﹤0.01% 4282
2022
Q2 		$48K Sell
2,101
-13,072
-86% -$358K ﹤0.01% 4352
2022
Q1 		$679K Buy
15,173
+649
+4% +$25.6K ﹤0.01% 3528
2021
Q4 		$559K Buy
14,524
+247
+2% +$11.2K ﹤0.01% 3737
2021
Q3 		$724K Buy
14,277
+985
+7% +$49.4K ﹤0.01% 3591
2021
Q2 		$1.16M Buy
13,292
+11,191
+533% +$673K ﹤0.01% 3311
2021
Q1 		$94K Buy
+2,101
New +$83.7K ﹤0.01% 4174

Other funds holding CTXR

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fisher Asset Management
Fisher Asset Management Camas, Washington $336B AUM 34.66% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return

Bank of New York Mellon's CTXR Position: Q4 2024 in Review

Bank of New York Mellon sold out of Citius Pharmaceuticals (CTXR) in Q4 2024, closing a stake of 585 shares — an estimated $7.33K sold.

Bank of New York Mellon first reported a position in CTXR in Q1 2021 and held it in 15 quarters. The position peaked at $1.16M in Q2 2021. 30 funds tracked by Wall St. Rank hold CTXR as of Q4 2024.

  • Bank of New York Mellon reported no remaining Citius Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Bank of New York Mellon sold 585 Citius Pharmaceuticals shares in Q4 2024, an estimated $7.33K.
  • Bank of New York Mellon first reported a position in Citius Pharmaceuticals in Q1 2021 and held it in 15 quarters.
  • Bank of New York Mellon's Citius Pharmaceuticals position peaked at $1.16M in Q2 2021.
  • 30 funds tracked by Wall St. Rank held Citius Pharmaceuticals as of Q4 2024.

Based on Bank of New York Mellon's 13F filing for Q4 2024, filed 4 Feb 2025.